title: [The use of tissue plasminogen activator in the post-operative treatment of fibrinoid uveitis].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of tissue plasminogen activator in management of postoperative fibrinous uveitis.
  
  
  METHODS
  Prospective study, interventional case series including 13 patients who developed fibrinous membrane in anterior chamber; patients were operated for cataract (4 cases), for cataract and glaucoma (7 cases) and for corneoscleral lacerations (2 cases). Initial treatment consisted of corticosteroid administration (topically, subconjunctival +/- systemic) and mydriatic-cycloplegic drugs. Inadequate response imposed intracavitary administration of tissue plasminogen activator (25 microg/ml, 0.2 ml). The main outcomes were: complete resolution of fibrinous membrane, presence of adverse events and visual rehabilitation.
  
  
  RESULTS
  Fibrinous membrane resorption starts in the next hours and complete resolution was proved in all cases after a mean time 53.55 +/- 37.65 (24-146) hours. In 12 patients we used only one administration of tissue plasminogen activator, but in one case we repeated it. It was not signaled any adverse event drug related. It was an important increase of visual acuity in all cases.
  
  
  CONCLUSIONS
  Intracavitary administration of tissue plasminogen activator is a safe and efficient alternative in the management of postoperative fibrinous membrane.
authors.affiliation: Spitalul Clinic Universitar "SF. Spiridon", Iaşi.
authors.forename: Dorin
authors.initials: D
authors.lastname: Chiseliţă
authors.forename: Ingrid
authors.initials: I
authors.lastname: Antohi
authors.forename: Daniela
authors.initials: D
authors.lastname: Cionca
authors.forename: Radu
authors.initials: R
authors.lastname: Medvichi
authors.forename: Diana
authors.initials: D
authors.lastname: Cimpoeşu
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D002387:Cataract Extraction / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005128:Eye Diseases / Q000601:surgery; D005260:Female; D005337:Fibrin / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014605:Uveitis / Q000188:drug therapy* / Q000473:pathology; D014792:Visual Acuity
chemical_list: D000305:Adrenal Cortex Hormones; D005343:Fibrinolytic Agents; D005337:Fibrin; D010959:Tissue Plasminogen Activator